Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion type Assertion NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_head.
- NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion description "[EMSY amplification was seen in 52/285 (18%) high grade papillary serous carcinomas, 4/27 (15%) high grade endometrioid carcinomas, 3/38 (8%) clear cell carcinomas, and 3/10 (30%) undifferentiated carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_provenance.
- NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion evidence source_evidence_literature NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_provenance.
- NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion SIO_000772 16236351 NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_provenance.
- NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion wasDerivedFrom befree-20150227 NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_provenance.
- NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_assertion wasGeneratedBy ECO_0000203 NP924911.RAFl2cV6fpz734oDSWbrRu3t2ibRiTcL0xDUps7shd2sM130_provenance.